Preparatory Work to Assess Adherence to Oral Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-20

Study Completion Date

2017-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study to find out more about how patients take their anticancer medications and challenges related to taking cancer medications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Validation of a Novel Adherence Method for Oral Oncolytics

NCT03561272

Cancer

COMPLETED NA

Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication

NCT03104114

Adherence, Medication

COMPLETED NA

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

NCT04663100

Chronic Myeloid Leukemia Chronic Lymphocytic Leukemia Multiple Myeloma +1 more

RECRUITING NA

Smartphone App for Cancer Medication Adherence

NCT05225090

Carcinoma Cancer

COMPLETED NA

Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications

NCT02833246

Sarcoma Lung Solid Tumor Gastrointestinal

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

120 patients with Chronic Myeloid Leukemia (CML) who are currently prescribed an oral anti-cancer agent from up to 6 CCDR NCORP sites to complete a brief interviewer administered survey to assess medication adherence and related factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral Anti-Cancer Agent

No intervention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is diagnosed with Chronic Myeloid Leukemia (CML) and is receiving care for CML at a participating CCDR NCORP practice,
* Patient had been prescribed one of the following oral anticancer agents for CML for ≥30 days (Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib). Prior use of any of these medications is allowed, as long as they have been on a stable regimen for at least 30 days prior to enrollment.
* Patient is 18 years of age or older

Exclusion Criteria

* Patient does not speak English or requires an interpreter for medical visits
* Patient is cognitively impaired, as determined by the referring provider

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No